Polypharmacology of clinical sodium glucose co‐transport protein 2 inhibitors and relationship to suspected adverse drug reactions

• Váldodahkkit: Karan Matharu (Dahkki), Kiran Chana (Dahkki), Charles J. Ferro (Dahkki), Alan M. Jones (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2021-10-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Sodium glucose co‐transporter 2 inhibitors (SGLT2i) are a promising second‐line treatment strategy for type 2 diabetes mellitus (T2DM) with a developing landscape of both beneficial cardio‐ and nephroprotective properties and emerging adverse drug reactions (ADRs) including diabetic ketoaci...